Skip to main content

16-04-2024 | Type 2 Diabetes | Editor's Choice | News

ACC 2024

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Author: Laura Cowen

medwireNews: Weekly treatment with semaglutide reduces heart failure symptoms, physical limitations, and body weight, relative to placebo, among people with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, study findings indicate.

Related topics